Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Oncotype DX® GPS (Prostate)

The Oncotype DX Genomic Prostate Score (GPS) assay analyzes the expression of 17 genes to predict the biological aggressiveness of prostate cancer.

Evidence-based context for fast calculator use

Purpose:
Oncotype DX GPS assesses prostate cancer genomic aggressiveness to guide active surveillance versus definitive treatment decisions.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
GPS Score, NCCN Clinical Risk Group
Reference:
Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550-560.
HomeOncotype DX® GPS (Prostate)
Pin your most used calculators here by clicking the star in the dropdown.

Oncotype DX® GPS (Prostate)

Clinical Context & Background

The Oncotype DX Genomic Prostate Score (GPS) assay analyzes the expression of 17 genes to predict the biological aggressiveness of prostate cancer. It is validated for use in men with clinically localized prostate cancer (NCCN Very Low, Low, and Intermediate Risk) to help guide treatment decisions, particularly regarding Active Surveillance.
Primary Source EvidenceKlein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550-560.
Formula Logic
GPS Score (0-100) based on 17-gene signature.

Reference Data

GPS ScoreRisk ProfileAdverse Pathology Risk
0 - 20Very LowLow risk of adverse pathology
21 - 40Low / IntermediateIntermediate risk
41 - 100HighHigh risk of adverse pathology

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Oncotype DX® GPS (Prostate) when oncotype DX GPS assesses prostate cancer genomic aggressiveness to guide active surveillance versus definitive treatment decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 20 through 41 - 100.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify GPS Score, NCCN Clinical Risk Group, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)

Frequently Asked Questions

When should Oncotype DX® GPS (Prostate) be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can Oncotype DX® GPS (Prostate) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.